WHO ICTRP trial
Investigation of AV411 in neuropathic pain
ACTRN12606000403538 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12606000403538 |
|---|---|
| Public title | Investigation of AV411 in neuropathic pain |
| Scientific title | A prospective, double-blind, randomized, placebo-controlled trial of AV411 to assess its safety tolerability, pharmacokinetics and preliminary efficacy in the treatment of neuropathic pain |
| Primary sponsor | Avigen, Inc. |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 1 / Phase 2 |
| Countries | Australia |
| Conditions | Diabetic neuropathy or Complex regional pain syndrome; Diabetic neuropathy or Complex regional pain syndrome;Metabolic and Endocrine - Diabetes;Neurological - Pain management |
| Interventions | Oral AV411 (20, 30, or 40 mg) two or three times daily for 24 days |
| Registration date | Sep 13, 2006 |
| Target size | 36 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: